Switch theme
Sign up to access all valuation multiples
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
2001
766
LTM Revenue $343M
LTM EBITDA -$5.3M
$73.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inogen has a last 12-month revenue (LTM) of $343M and a last 12-month EBITDA of -$5.3M.
In the most recent fiscal year, Inogen achieved revenue of $336M and an EBITDA of -$21.5M.
Inogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $343M | XXX | $336M | XXX | XXX | XXX |
| Gross Profit | $156M | XXX | $155M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | -$5.3M | XXX | -$21.5M | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -6% | XXX | XXX | XXX |
| EBIT | -$36.4M | XXX | -$42.5M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -13% | XXX | XXX | XXX |
| Net Profit | -$32.5M | XXX | -$35.9M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Inogen's stock price is $6.
Inogen has current market cap of $173M, and EV of $73.1M.
See Inogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $73.1M | $173M | XXX | XXX | XXX | XXX | $-1.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Inogen has market cap of $173M and EV of $73.1M.
Inogen's trades at 0.2x EV/Revenue multiple, and -3.4x EV/EBITDA.
Equity research analysts estimate Inogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inogen has a P/E ratio of -5.3x.
See valuation multiples for Inogen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV (current) | $73.1M | XXX | $73.1M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | -13.8x | XXX | -3.4x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -4.8x | XXX | XXX | XXX |
| EV/FCF | 0.9x | XXX | -6.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInogen's last 12 month revenue growth is 6%
Inogen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Inogen's rule of 40 is -13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inogen's rule of X is 12% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inogen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Growth | -113% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -13% | XXX | -1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 12% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inogen acquired XXX companies to date.
Last acquisition by Inogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Inogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inogen founded? | Inogen was founded in 2001. |
| Where is Inogen headquartered? | Inogen is headquartered in United States of America. |
| How many employees does Inogen have? | As of today, Inogen has 766 employees. |
| Who is the CEO of Inogen? | Inogen's CEO is Mr. Kevin R. M. Smith. |
| Is Inogen publicy listed? | Yes, Inogen is a public company listed on NAS. |
| What is the stock symbol of Inogen? | Inogen trades under INGN ticker. |
| When did Inogen go public? | Inogen went public in 2014. |
| Who are competitors of Inogen? | Similar companies to Inogen include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Inogen? | Inogen's current market cap is $173M |
| What is the current revenue of Inogen? | Inogen's last 12 months revenue is $343M. |
| What is the current revenue growth of Inogen? | Inogen revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Inogen? | Current revenue multiple of Inogen is 0.2x. |
| Is Inogen profitable? | Yes, Inogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Inogen? | Inogen's last 12 months EBITDA is -$5.3M. |
| What is Inogen's EBITDA margin? | Inogen's last 12 months EBITDA margin is -2%. |
| What is the current EV/EBITDA multiple of Inogen? | Current EBITDA multiple of Inogen is -13.8x. |
| What is the current FCF of Inogen? | Inogen's last 12 months FCF is $83.5M. |
| What is Inogen's FCF margin? | Inogen's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Inogen? | Current FCF multiple of Inogen is 0.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
